Tango Therapeutics News

Express News | Tango Therapeutics Shares Are Trading Higher After Cantor Fitzgerald Initiated Coverage on the Stock With an Overweight Rating

Moomoo 24/7Apr 4 07:55 ET

Express News | Cantor Fitzgerald Initiates Coverage On Tango Therapeutics With Overweight Rating

Moomoo 24/7Apr 4 07:02 ET

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PDF Version BOSTON--(BUSINESS WIRE)--Apr. 1, 2024-- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of

Tango TherapeuticsApr 1 00:00 ET

Earnings Update: Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported And Analysts Are Boosting Their Estimates

Tango Therapeutics, Inc. (NASDAQ:TNGX) shareholders are probably feeling a little disappointed, since its shares fell 7.8% to US$8.50 in the week after its latest yearly results. Despite revenue

Simply Wall StMar 21 06:43 ET

Buy Rating Affirmed for Tango Therapeutics on Strong Pipeline and Financial Stability

TipRanksMar 21 02:17 ET

Tango Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Tango Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 20 07:06 ET

Express News | HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $17

Moomoo 24/7Mar 20 06:56 ET

Tango Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/20/2024 119.64% HC Wainwright & Co. $16 → $17 Maintains Buy 02/12/2024 132.56% Piper Sandler → $18 Init

BenzingaMar 20 06:54 ET

Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results

Yahoo FinanceMar 20 05:31 ET

AQST,CDXS and STI Are Among After Hour Movers

Seeking AlphaMar 19 17:37 ET

Insiders Sold Tango Therapeutics At US$11.59, Meanwhile Stock Sits Near US$8.39

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) value has fallen 22% in the last week, but insiders who sold US$365k worth of stock over the last year have had less success. Insiders would probably have bee

Simply Wall StMar 19 07:48 ET

Tango Therapeutics (TNGX) Receives a Buy From Barclays

TipRanksMar 19 06:21 ET

Navigating the AI Minefield: Tango Therapeutics' Struggle With Security Risks and EU Regulations

TipRanksMar 19 02:00 ET

Express News | Tango Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q4 Financial Results

Moomoo 24/7Mar 18 13:25 ET

Recap: Tango Therapeutics Q4 Earnings

Tango Therapeutics (NASDAQ:TNGX) reported its Q4 earnings results on Monday, March 18, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsTango Therapeutics missed esti

BenzingaMar 18 10:05 ET

Express News | Tango Therapeutics' Cash Position Of $337M As Of December 31, 2023, Combined With $42M In Proceeds From ATM In January 2024 Is Expected To Provide Cash Runway Into Late 2026

Moomoo 24/7Mar 18 07:44 ET

Tango Therapeutics GAAP EPS of -$0.32 Misses by $0.04, Revenue of $5.43M Misses by $2.81M

Seeking AlphaMar 18 07:11 ET

Tango Therapeutics: Dose Escalation Ongoing in Four Clinical-Stage Precision Oncology Programs; TNG908 Phase 1/2 Clinical Data Expected in 2024 >TNGX

Tango Therapeutics: Dose Escalation Ongoing in Four Clinical-Stage Precision Oncology Programs; TNG908 Phase 1/2 Clinical Data Expected in 2024 >TNGX

Dow JonesMar 18 07:02 ET

Tango Therapeutics 4Q Loss/Shr 32c >TNGX

Tango Therapeutics 4Q Loss/Shr 32c >TNGX

Dow JonesMar 18 07:01 ET

Press Release: Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights

Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights -- Dose escalation ongoing in four clinical-stage precision oncology programs; TNG908 p

Dow JonesMar 18 07:00 ET